309
Participants
Start Date
May 15, 2014
Primary Completion Date
May 4, 2016
Study Completion Date
May 4, 2016
BAY1002670
Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
BAY1002670
Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
BAY1002670
Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
BAY1002670
Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Placebo
Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Bruxelles - Brussel
Bruxelles - Brussel
Sofia
Sofia
Sellebakk
Sofia
Leuven
Bern
Liège
Debrecen
Debrecen
Nesttun
Pleven
Charleroi
Stara Zagora
Kecskemét
Szentes
Szeged
Trondheim
Trondheim
New York
Berlin
Prague
Prague
Pittsburgh
Philadelphia
Philadelphia
Washington D.C.
Norfolk
Lübeck
Raleigh
Durham
Aravaca
Sandy Springs
Ilsede
Jacksonville
Gainesville
South Miami
Plantation
Chattanooga
Blankenburg
Písek
Seville
Seville
Columbus
Cleveland
Valencia
Newburgh
Geseke
Naperville
Lincoln
Marrero
Kuopio
Frisco
Dallas
Karlsruhe
Houston
Houston
Joensuu
Denver
Mesa
Tucson
Oulu
Erlangen
San Diego
San Diego
Seattle
Southington
Moorestown
Neptune City
New Brunswick
Portland
Pittsburgh
Winnipeg
Hamilton
Ottawa
Pointe-Claire
Québec
České Budějovice
Hradec Králové
Olomouc
Espoo
Helsinki
Dresden
Bernburg
Matsudo
Iizuka
Kōriyama
Sapporo
Sapporo
Kanazawa
Ōmura
Numazu
Kita-ku
Nakano-ku
Tacchikawa
Kumamoto
Nagano
Oslo
Barcelona
Barcelona
Gothenburg
Örebro
Stockholm
Uppsala
Lead Sponsor
Bayer
INDUSTRY